Intranasal Insulin Shows promise in Delivering Alzheimer’s Treatment Directly to the Brain

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide.Characterized by progressive memory loss and cognitive decline, AD currently lacks a cure, and existing treatments offer only limited symptomatic relief. However, recent research offers a glimmer of hope: a novel approach utilizing intranasal insulin delivery to directly target key brain regions affected by the disease. This method aims to bypass challenges associated with conventional drug delivery to the brain, perhaps revolutionizing AD treatment.

The Challenge of Brain Drug Delivery

One of the biggest hurdles in developing effective AD therapies is the blood-brain barrier (BBB). This protective mechanism shields the brain from harmful substances but also restricts the passage of many potentially therapeutic drugs.Consequently, delivering sufficient concentrations of medication to the brain remains a notable obstacle.

Researchers have been exploring choice routes, such as intranasal delivery, to circumvent the BBB. The nasal cavity provides a direct pathway to the brain via the olfactory and trigeminal nerves,offering a less invasive and potentially more efficient means of drug management. Though, confirming that the drug is actually reaching its intended brain targets is critical for designing accomplished trials.

Intranasal Insulin for AD: A First-in-Human Study

To further assess how intranasal insulin reaches the brain, researchers recently conducted a first-in-human positron emission tomography (PET) study involving 16 older adults with an average age of 72. The cohort included seven cognitively normal individuals and nine with mild cognitive impairment (MCI), a stage often preceding AD.

The study utilized a novel radiotracer, [68Ga]Ga-NOTA-insulin, and a convenient 6-spray delivery system. Participants underwent brain and whole-body imaging, and reported the spray was easy to use. This innovative approach allowed researchers to visualize and quantify insulin uptake in the brain in real-time.

Key Findings: Insulin Reaches target Brain Regions

The results were highly encouraging. The study demonstrated significant insulin uptake in crucial memory regions,including the hippocampus and temporal lobe – areas heavily impacted by AD pathology. Importantly, cognitively normal individuals exhibited higher and more sustained insulin absorption compared to those with MCI, suggesting a potential link between insulin transport and cognitive function.Further analysis revealed intriguing correlations. In women, insulin uptake was associated with better cardiovascular health, highlighting the interconnectedness of brain and systemic health. Conversely, a marker of brain amyloid levels – a hallmark of AD – was linked with reduced brain absorption of insulin. This suggests amyloid plaques may interfere with insulin transport, offering a potential therapeutic target.

“The results of the study represent a significant step forward in medicine, as they validate that our nasal delivery system was effective in delivering intranasal insulin safely and effectively to specific regions of the brain,” stated Reenal Gandhi, director of business development for Aptar Pharma. “As scientific understanding and development advance, we see continued opportunities for intranasal delivery to improve how therapeutics are delivered to the central nervous system.”

Safety and Tolerability

The treatment was remarkably well-tolerated by participants. only two individuals reported mild,short-lived headaches,indicating a favorable safety profile. This is a crucial factor for any potential new therapy, particularly for a vulnerable population like those at risk for or diagnosed with AD.

“While there’s still a lot to learn, these findings show that we now have the tools to validate intranasal drug delivery to the brain,” concluded study lead, Dr. Craft. “This is promising news for developing more effective and accessible treatments for AD.”

REFERENCES

1. Sai K. erichsen J. Gollapelli K. et al.First-in-human positron emission tomography study of intranasal insulin in aging and MCI.Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Volume 11 (2025) doi.org/10.1002/trc2.70123
2. New study validates insulin nasal spray to deliver Alzheimer’s drug directly to the brain. EurekAlert! News release. July 23, 2025. Accessed August 8, 2025. https://www.eurekalert.org/news-releases/1092108
3. Alzheimer’s Disease. Mayo Clinic. News release. November 8, 2024. Accessed August 5, 2025. https://www.mayoc